Our studies highlight the importance of KCa1.1 on FLS and Kv1.3 on TEM cells as moderators of disease severity in RA, and they further validate the use of selective, potent potassium channel blockers as novel therapies for RA. This evidence concerns the gene KCNMA1 and rheumatoid arthritis.